Stocks and Investing
Stocks and Investing
Fri, August 24, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, August 23, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Charles Duncan Initiated (ACAD) at Buy and Held Target at $25 on, Aug 23rd, 2018
Charles Duncan of Cantor Fitzgerald, Initiated "ACADIA Pharmaceuticals Inc." (ACAD) at Buy and Held Target at $25 on, Aug 23rd, 2018.
Charles has made no other calls on ACAD in the last 4 months.
There are 2 other peers that have a rating on ACAD. Out of the 2 peers that are also analyzing ACAD, 1 agrees with Charles's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Matteis Paul of "Stifel" Maintained at Hold with Decreased Target to $14 on, Thursday, August 9th, 2018
This is the rating of the analyst that currently disagrees with Charles
- Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $27 on, Thursday, August 9th, 2018